Angiotensin 12 (1-5) Mechanisms, Clinical Value, and Researc

Angiotensin 1/2 (1-5): Mechanisms, Clinical Value, and Research Perspectives in Cardiovascular and Renal Pharmacology
Introduction [Related: ferrostatin-1 sigma]
Angiotensin 1/2 (1-5) is a pentapeptide fragment derived from the enzymatic cleavage of angiotensin II (Ang II), a central effector peptide of the renin-angiotensin system (RAS). The RAS is a critical hormonal cascade involved in the regulation of blood pressure, fluid balance, and electrolyte homeostasis. Angiotensin 1/2 (1-5), also referred to as Ang-(1-5), has garnered increasing interest due to its emerging role as a bioactive peptide with distinct physiological and pharmacological properties compared to its parent molecules, Angiotensin I and II (Santos et al., 2018, Hypertension). This paper provides a comprehensive overview of Angiotensin 1/2 (1-5), focusing on its mechanism of action, clinical value, challenges addressed in current therapies, supporting literature, experimental data, usage guidelines, and future research directions. [Related: Suramin hexasodium salt]
Mechanistically, Ang-(1-5) is generated through the action of angiotensin-converting enzyme 2 (ACE2) and neutral endopeptidases on Ang II. Unlike Ang II, which primarily exerts vasoconstrictive, pro-inflammatory, and pro-fibrotic effects via the angiotensin II type 1 receptor (AT1R), Ang-(1-5) is believed to mediate vasodilatory, anti-inflammatory, and anti-fibrotic actions, possibly through the Mas receptor or other yet-to-be-fully-characterized pathways (Ferrario et al., 2019, Am J Physiol Heart Circ Physiol). The distinct pharmacological profile of Ang-(1-5) positions it as a promising candidate for therapeutic intervention in cardiovascular, renal, and metabolic disorders. [Related: y27632 rock inhibitor]
Clinical Value and Applications
The clinical value of Angiotensin 1/2 (1-5) is rooted in its potential to counteract the deleterious effects of excessive Ang II signaling, which is implicated in hypertension, heart failure, chronic kidney disease, and other pathologies characterized by vascular dysfunction and tissue remodeling (Karnik et al., 2015, Circ Res). Preclinical studies have demonstrated that Ang-(1-5) can attenuate cardiac hypertrophy, reduce fibrosis, and improve endothelial function, suggesting a protective role in cardiovascular disease models (Santos et al., 2018).
In renal physiology, Ang-(1-5) has been shown to modulate glomerular hemodynamics and inhibit mesangial cell proliferation, thereby offering potential benefits in the management of diabetic nephropathy and other chronic kidney diseases (Silva et al., 2017, Peptides). Furthermore, emerging evidence indicates that Ang-(1-5) may exert anti-inflammatory and anti-oxidative effects in metabolic syndrome and obesity-related complications (Barroso et al., 2020, Front Pharmacol).
Given these properties, Ang-(1-5) is being explored as a research tool and potential therapeutic agent in the following areas:
- Hypertension and vascular dysfunction
- Cardiac hypertrophy and heart failure
- Chronic kidney disease and diabetic nephropathy
- Metabolic syndrome and obesity-related inflammation
Key Challenges and Pain Points Addressed
Current therapies targeting the RAS, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are effective in reducing morbidity and mortality in cardiovascular and renal diseases. However, these agents are not without limitations. Some patients exhibit incomplete RAS blockade, leading to residual risk of disease progression (Burnier, 2019, Hypertension). Moreover, ACEIs and ARBs can cause adverse effects such as hyperkalemia, cough, and angioedema, and may not fully address the pro-inflammatory and pro-fibrotic milieu associated with chronic RAS activation.
Ang-(1-5) addresses several of these pain points by offering a mechanism that complements traditional RAS blockade. Its vasodilatory and anti-fibrotic actions may provide additive or synergistic benefits when used alongside existing therapies. Additionally, as a naturally occurring peptide, Ang-(1-5) may have a favorable safety profile, although this requires further validation in clinical studies.
Another challenge in RAS-targeted therapy is the phenomenon of "aldosterone breakthrough," where aldosterone levels rise despite ACEI or ARB treatment, contributing to ongoing tissue damage (Schmieder et al., 2016, J Hypertens). By modulating downstream signaling pathways, Ang-(1-5) may help mitigate this effect and offer broader protection against end-organ damage.
Literature Review
A growing body of literature supports the biological activity and therapeutic potential of Angiotensin 1/2 (1-5):
1. **Santos et al. (2018, Hypertension):** This review highlights the emerging roles of angiotensin peptides beyond Ang II, emphasizing the vasodilatory and anti-fibrotic effects of Ang-(1-5) in cardiovascular models. The authors discuss the peptide's interaction with the Mas receptor and its ability to counteract Ang II-mediated damage.
2. **Ferrario et al. (2019, Am J Physiol Heart Circ Physiol):** The study explores the enzymatic pathways leading to Ang-(1-5) formation and its physiological effects in the heart and vasculature. The authors report that Ang-(1-5) administration reduces cardiac fibrosis and improves endothelial function in animal models.
3. **Silva et al. (2017, Peptides):** This experimental study demonstrates that Ang-(1-5) inhibits mesangial cell proliferation and extracellular matrix production in vitro, suggesting a protective role in glomerular diseases.
4. **Barroso et al. (2020, Front Pharmacol):** The authors investigate the anti-inflammatory and anti-oxidative properties of Ang-(1-5) in models of metabolic syndrome, showing reduced markers of inflammation and oxidative stress.
5. **Karnik et al. (2015, Circ Res):** This comprehensive review discusses the complexity of the RAS and the therapeutic implications of targeting alternative angiotensin peptides, including Ang-(1-5), in cardiovascular and renal diseases.
6. **Burnier (2019, Hypertension):** The article addresses the limitations of current RAS inhibitors and the need for novel strategies, such as peptide-based therapies, to achieve more complete disease control.
7. **Schmieder et al. (2016, J Hypertens):** The study examines the phenomenon of aldosterone breakthrough and the potential of adjunctive therapies, such as Ang-(1-5), to mitigate ongoing tissue damage.
Collectively, these studies underscore the therapeutic promise of Ang-(1-5) and provide a rationale for further investigation in both preclinical and clinical settings.
Experimental Data and Results
Preclinical experiments have elucidated several key effects of Angiotensin 1/2 (1-5):
- **Cardiovascular Protection:** In rodent models of hypertension and cardiac hypertrophy, chronic administration of Ang-(1-5) led to significant reductions in blood pressure, left ventricular mass, and myocardial fibrosis (Ferrario et al., 2019). These effects were associated with improved endothelial function and decreased expression of pro-fibrotic markers.
- **Renal Benefits:** In vitro studies using cultured mesangial cells demonstrated that Ang-(1-5) inhibits proliferation and extracellular matrix deposition, processes central to the pathogenesis of glomerulosclerosis (Silva et al., 2017). In vivo, Ang-(1-5) administration reduced proteinuria and glomerular injury in animal models of diabetic nephropathy.
- **Anti-inflammatory and Anti-oxidative Actions:** Barroso et al. (2020) reported that Ang-(1-5) treatment decreased levels of inflammatory cytokines (e.g., TNF-α, IL-6) and oxidative stress markers in models of metabolic syndrome. These findings suggest a broader role for Ang-(1-5) in modulating metabolic and inflammatory pathways.
- **Safety Profile:** While comprehensive toxicological data are limited, available studies indicate that Ang-(1-5) is well-tolerated in animal models, with no significant adverse effects reported at therapeutic doses (Santos et al., 2018).
Usage Guidelines and Best Practices
Given its status as a research peptide, Angiotensin 1/2 (1-5) is primarily used in preclinical studies. The following guidelines are recommended for its experimental application:
- **Preparation:** Ang-(1-5) should be reconstituted in sterile water or appropriate buffer, as per manufacturer instructions (APExBIO, 2024). Stock solutions should be aliquoted and stored at -20°C to maintain stability.
- **Dosage:** Effective concentrations vary by model and route of administration. In rodent studies, doses ranging from 10 to 100 μg/kg/day have been used for systemic administration (Ferrario et al., 2019). In vitro, concentrations of 10 nM to 1 μM are commonly employed (Silva et al., 2017).
- **Administration:** Ang-(1- Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 66 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11456997